Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-09-13
2009-08-11
Campell, Bruce (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S070200, C424S133100, C424S139100, C435S141000, C435S147000, C435S178000, C435S345000
Reexamination Certificate
active
07572456
ABSTRACT:
The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.
REFERENCES:
patent: 2003/0148261 (2003-08-01), Fikrig et al.
patent: 2006/0067940 (2006-03-01), Diamond et al.
patent: 2006/0115837 (2006-06-01), Fremont et al.
Oliphant et al., Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus, Nature Medicine, May 2005, vol. 11, No. 5, pp. 522-530.
Nybakken et al., Structural basis of West Nile virus neutralization by a therapeutic antibody, Nature, Sep. 2005, vol. 437, No. 29, pp. 764-768.
Roehrig et al., Antibody prophylaxis and therapy for flavivirus encephalitis infections, Annals of the New York Academy of Sciences, Dec. 2001, vol. 951, pp. 286-297.
Beasley et al., Identification of Neutralizing Epitopes within Structural Domain III of the West Nile Virus Envelope Protein, Journal of Virology, Dec. 2002, vol. 76, No. 24, pp. 13097-13100.
U.S. Appl. No. 60/581,819, filed Feb. 21, 2004, Diamond et al.
U.S. Appl. No. 60/609,766, filed Sep. 13, 2004, Johnson et al.
Agrawal et al., 2003, “Human immunoglobulin as a treatment for West Nile virus infection,” J. Infect. Dis. 188(1):1-4.
Allison et al., 1999, “Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E,” J. Virol. 73(7):5605-12.
Anderson et al., 2002, “Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro,” Emerg. Infect. Dis. 8(1):107-8.
Asnis et al., 2000, “The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience,” Clin. Infect. Dis. 30(3):413-8.
Beasley et al., 2001, “Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies,” Virology 279(2):447-58.
Beasley et al., 2002, “Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein,” J. Virol. 76(24):13097-100.
Ben-Nathan et al., 1996, “West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice,” Arch. Virol. 141(3-4):459-69.
Ben-Nathan et al., 2003, “Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice,” J. Infect. Dis. 188(1):5-12.
Brandriss et al., 1986, “Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses,” J. Gen. Virol. 67 ( Pt 2):229-34.
Broom et al., 2000, “Immunisation with gamma globulin to Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: Evaluation in a mouse model,” J. Med. Virol. 61:259-265.
Camenga et al., 1974, “Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors,” J. Infect. Dis. 130(6):634-41.
Cardosa et al., 1986, “Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement,” J. Virol. 57(3):952-9.
Cecilia et al., 1991, “Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants,” Virology 181(1):70-7.
Chambers et al., 1990, “Flavivirus genome organization, expression, and replication,” Annu. Rev. Microbiol. 44:649-88.
Chiba et al., 1999, “Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization,” Vaccine 17(11-12):1532-9.
Chu et al., 2005, “Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein,” J. Gen. Virol. 86(Pt 2):405-12.
Crill et al., 2001, “Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells,” J. Virol. 75(16):7769-73.
Diamond et al., 2000, “Infection of Human Cells by Dengue Virus Is Modulated by Different Cell Types and Viral Strains,” J. Virol 74:7814-7823.
Diamond et al., 2003, “A critical role for induced IgM in the protection against West Nile virus infection,” J. Exp. Med. 198(12):1853-62.
Diamond et al., 2003, “B Cells and Antibody Play Critical Roles in the Immediate Defense of Disseminated Infection by West Nile Encephalitis Virus,” J. Virol. 77:2578-2586.
Diamond et al., 2003, “Innate and Adaptive Immune Responses Determine Protection against Disseminated Infection by West Nile Encephalitis Virus,” Viral Immunol. 16(3):259-278.
Eisenstein, 2005, “Antibody neutralizes West Nile virus,” Lab. Anim. (NY) 34(6):10.
Engle et al., 2003, “Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice,” J. Virol. 77(24):12941-9.
Falconar et al., 1999, “Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins,” Arch. Virol. 144(12):2313-30.
Goncalvez et al., 2004, “Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses,” J. Virol. 78(23):12910-8.
Halevy et al., 1994, “Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice,” Arch. Virol. 137(3-4):355-70.
Haley et al., 2003, “The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis,” Clin. Infect. Dis. 37(6):e88-90.
Halstead et al., 1980, “Enhancement of dengue virus infection in monocytes by flavivirus antisera,” Am. J. Trop. Med. Hyg. 29(4):638-42.
Halstead et al., 1989, “Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade,” Rev. Infect. Dis. Suppl 4:S830-9.
Hamdan et al., 2002, “Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis,” Transpl. Infect. Dis. 4(3):160-2.
Henchal et al., 1988, “Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus,” J. Gen. Virol. 69 ( Pt. 8):2101-7.
Holgate et al., 2001, “Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality,” Curr. Med. Res. Opin. 17(4):233-40.
Julander et al., 2005, “Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival,” Antiviral Res. 65(2):79-85.
Kimura-Kuroda et al., 1988, “Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies,” J. Immunol. 141(10):3606-10.
Kishore et al., 2000, “C1q: structure, fun
Huang Ling
Johnson Leslie S.
Campell Bruce
Drinker Biddle & Reath LLP
Hurt Sharon
MacroGenics, Inc.
LandOfFree
Humanized antibodies against West Nile Virus and therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies against West Nile Virus and therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies against West Nile Virus and therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4083289